Guidance on changing therapy choice in myelofibrosis.
作者信息
McLornan Donal P, Harrison Claire N
机构信息
Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.
出版信息
Blood Adv. 2020 Feb 25;4(4):607-610. doi: 10.1182/bloodadvances.2019001426.
Abstract
摘要
相似文献
1
Guidance on changing therapy choice in myelofibrosis.骨髓纤维化治疗方案变更指南。
Blood Adv. 2020 Feb 25;4(4):607-610. doi: 10.1182/bloodadvances.2019001426.
2
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704.
3
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2031-2; author reply 2032-4. doi: 10.1056/NEJMc1203704.
4
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2031; author reply 2032-4. doi: 10.1056/NEJMc1203704.
5
Hit the spleen, JAK!打中脾脏，JAK！
Blood. 2014 Nov 6;124(19):2898-900. doi: 10.1182/blood-2014-09-600635.
6
A phase 1 study of the Janus kinase 2 (JAK2) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.一项关于Janus激酶2（JAK2）抑制剂甘托替尼（LY2784544）用于原发性骨髓纤维化、真性红细胞增多症和原发性血小板增多症患者的1期研究。
Leuk Res. 2017 Oct;61:89-95. doi: 10.1016/j.leukres.2017.08.010. Epub 2017 Aug 31.
7
Myelofibrosis, JAK2 inhibitors and erythropoiesis.骨髓纤维化、JAK2抑制剂与红细胞生成
Leukemia. 2013 Jun;27(6):1219-23. doi: 10.1038/leu.2013.72.
8
A comprehensive review of pacritinib in myelofibrosis.帕西替尼治疗骨髓纤维化的综合综述。
Future Oncol. 2015;11(20):2819-30. doi: 10.2217/fon.15.200. Epub 2015 Sep 14.
9
[Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].[JAK抑制剂对骨髓纤维化影响的研究进展——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Feb;26(1):283-286. doi: 10.7534/j.issn.1009-2137.2018.01.050.
10
Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.JAK2抑制剂来他替尼治疗骨髓纤维化患者的II期试验。
Leuk Lymphoma. 2019 May;60(5):1343-1345. doi: 10.1080/10428194.2018.1532509. Epub 2019 Jan 22.
引用本文的文献
1
Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.亚洲经典费城染色体阴性骨髓增殖性肿瘤的管理：亚洲髓系工作组的共识。
Clin Exp Med. 2023 Dec;23(8):4199-4217. doi: 10.1007/s10238-023-01189-9. Epub 2023 Sep 25.
本文引用的文献
1
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.急变期骨髓增殖性肿瘤：来自两个独立队列的 410 例患者的 Mayo-AGIMM 研究。
Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.
2
Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.现行的骨髓纤维化患者管理治疗算法、JAK 抑制剂及其他。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):489-497. doi: 10.1182/asheducation-2017.1.489.
3
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.进退两难：评估芦可替尼停药后骨髓纤维化的挽救治疗及预后
Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30.
4
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.芦可替尼治疗骨髓纤维化患者的长期生存：COMFORT-I 和 -II 汇总分析。
J Hematol Oncol. 2017 Sep 29;10(1):156. doi: 10.1186/s13045-017-0527-7.
5
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.芦可替尼停药后骨髓纤维化的克隆进化与结局
Blood. 2017 Aug 31;130(9):1125-1131. doi: 10.1182/blood-2017-05-783225. Epub 2017 Jul 3.
6
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.在既往接受过鲁索替尼治疗的骨髓纤维化患者中使用Janus激酶2抑制剂非格司亭（JAKARTA-2）：一项单臂、开放标签、非随机、2期、多中心研究。
Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.
7
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.COMFORT-II的长期研究结果，这是一项关于芦可替尼与骨髓纤维化最佳可用疗法对比的3期研究。
Leukemia. 2017 Mar;31(3):775. doi: 10.1038/leu.2016.323.
8
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.芦可替尼用于骨髓纤维化患者的长期治疗：来自随机、双盲、安慰剂对照3期COMFORT-I试验的5年更新数据
J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z.
9
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.芦可替尼在骨髓纤维化患者中开展的一项开放标签、多中心、单臂3b期扩大准入研究中的安全性和有效性：JUMP试验中1144例患者的情况简述
Haematologica. 2016 Sep;101(9):1065-73. doi: 10.3324/haematol.2016.143677. Epub 2016 May 31.
10
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.Fedratinib 治疗原发性或继发性骨髓纤维化患者的安全性和疗效：一项随机临床试验。
JAMA Oncol. 2015 Aug;1(5):643-51. doi: 10.1001/jamaoncol.2015.1590.
Zotero 插件